Most staphylococci produce short a-type PSMs and about twice as long b-type PSMs that are potent leukocyte attractants and toxins. PSMs are usually secreted with the N-terminal formyl group but are only weak agonists for the leukocyte FPR1. Instead, the FPR1-related FPR2 senses PSMs efficiently and is crucial for leukocyte recruitment in infection. Which structural features distinguish FPR1 from FPR2 ligands has remained elusive. To analyze which peptide properties may govern the capacities of b-type PSMs to activate FPRs, fulllength and truncated variants of such peptides from Staphylococcus aureus, Staphylococcus epidermidis, and Staphylococcus lugdunensis were synthesized. FPR2 activation was observed even for short N-or Cterminal b-type PSM variants once they were longer than 18 aa, and this activity increased with length. In contrast, the shortest tested peptides were potent FPR1 agonists, and this property declined with increasing peptide length. Whereas full-length b-type PSMs formed a-helices and exhibited no FPR1-specific activity, the truncated peptides had less-stable secondary structures, were weak agonists for FPR1, and required N-terminal formylmethionine residues to be FPR2 agonists. Together, these data suggest that FPR1 and FPR2 have opposed ligand preferences. Short, flexible PSM structures may favor FPR1 but not FPR2 activation, whereas longer peptides with a-helical, amphipathic properties are strong FPR2 but only weak FPR1 agonists. These findings should help to unravel the ligand specificities of 2 critical human PRRs, and they may be important for new, anti-infective and anti-inflammatory strategies.
Introduction
The innate immune response is indispensable for the detection of invading microbial pathogens. Neutrophils are the first leukocytes infiltrating infected tissues. They become activated via PRRs, such as the TLRs or intracellular nucleotide-binding oligomerization domain receptors [1] [2] [3] . At early stages of infection, detection of bacteria occurs also via 7-transmembrane G-protein-coupled receptors, such as the FPRs [4] [5] [6] [7] . Stimulation of these receptors leads to chemotactic migration of leukocytes, which distinguishes FPRs from other PRRs. A gradient of bacterial derived, formylated peptides, resulting from the bacteria-specific start of protein biosynthesis with a formylated methionine, guides neutrophils to the focus of infection [4] . The FPR1, sensing formylated peptides at very low concentrations, is an important innate immune receptor at the surface of various leukocytes, including neutrophils and monocytes [8] . Whereas FPR1 is dedicated to the sensing of short formylated peptides, such as fMLF, 2 paralogs (FPR2 and FPR3) have only very low affinity for formylated peptides and respond efficiently to other types of peptide agonists [6, 9, 10] . FPR2 senses a variety of endogenous peptides, such as the human antimicrobial peptide LL-37 [11] . In addition, FPR2 strongly responds to PSMs, cytolytic and proinflammatory peptides secreted by S. aureus, S. epidermidis, and most other staphylococcal species [12] [13] [14] [15] . PSMs and other FPR2 ligands have only very limited sequence similarities and have been proposed to share a particular signature in their secondary structure [4, 6, 16, 17] . Notably, FPR1 responds with similar efficiency to most bacterial species, which all release formylated peptides, whereas FPR2 is specific for staphylococcal PSMs [13] and unknown peptides from enterococci [18] and Listeria monocytogenes [19] . As the virulence of staphylococci corresponds to the amounts of released PSMs, FPR2 can discriminate between highly and only weakly pathogenic staphylococcal strains [12] . Interestingly, although PSMs are secreted predominantly as formylated peptides, they activate FPR1 only very weakly [13, 20] Staphylococci produce 2 types of PSM peptides: a-type and b-type PSMs, consisting of 20-26 or ;44 aa, respectively [12, 17, 21] . d-Toxin represents 1 of the a-type PSMs [21] . All PSMs have a-helical, amphipathic structures [21] . In b-type PSMs, such as the S. aureus and S. epidermidis PSMb1, as well as the SLUSH-B, only the C-terminal parts of the peptides have been assumed to be a-helical [17] , but the actual secondary structures of b-type PSMs and the reasons why they are about twice as long as a-type PSMs have remained unknown. a-Type PSMs are, in general, more potent inducers of cell lysis and leukocyte activation than b-type PSMs [21] [22] [23] . However, b-type PSMs are usually secreted at higher concentrations than a-type PSMs, except d-toxin, by different staphylococcal species [21, 24] . All PSMs, with the exception of the S. aureus PSM-mec, are core-genome encoded. The PSM-mec gene is located on a mobile genetic element [25] . It has been shown recently that PSMs are exported via the S. aureus ATP-binding cassette phenol-soluble modulin transporter (Pmt) that is essential for bacterial growth and contributes to producer immunity to secreted PSMs, which may exert antimicrobial activities at very high concentrations [26] .
Staphylococci cause many types of infection. S. aureus is one of the most frequent causes of nosocomial and community-associated infections, including skin infections, abscesses, endocarditis, and sepsis [27] . In contrast to S. aureus, most coagulase-negative staphylococci have only a few virulence genes [28] . Many S. aureus strains produce chemotaxis inhibitory protein of S. aureus, FLIPr, and FLIPr-like, specific inhibitors of the human FPR1, FPR2, or both receptors, respectively [29] [30] [31] . These proteins are thought to enable the producing strains to remain unrecognized by the human innate immune defense during early stages of infection. The fact that S. aureus secretes these inhibitors underscores that FPRs are important receptors for the detection of bacteria and that disrupting these pathways may be a suitable strategy to modulate the activation of innate immune responses.
Here ,we analyzed whether b-type PSMs need their entire length for exerting their proinflammatory and cytolytic activities, and which part of the b-peptides is responsible for FPR2 activation. With the use of collections of b-type PSM congeners, we provide evidence that a peptide length of at least 18 aa, in combination with an N-terminal formylated methionine, favors FPR2 activation by PSMs, whereas a shorter sequence with a flexible folding state favors the capacity of formylated peptides to stimulate FPR1.
MATERIALS AND METHODS

Synthetic peptide and antibodies
S. lugdunensis and S. epidermidis PSM peptides were synthesized by EMC Microcollections (Tuebingen, Germany) and S. aureus PSMs by BACHEM (Bubendorf, Switzerland), with or without N-terminal formylation. The sequences of full-length and truncated peptides are given in Table 1 . The SLUSH-B was also synthesized with reversed amino acid sequence for control studies, SLUSH-Brev. Antibodies against human FPR1 (mouse anti-human FPR1 MAB3744, isotype control MAB0031, and rat anti-mouse IgG2a-PE) were purchased from R&D Systems (Minneapolis, MN, USA). Antibodies against human FPR2 were purchased from Genovac (Freiburg, Germany; mouse anti human FPR2, FN-1D6-A1) and from SouthernBiotech (Birmingham, AL, USA; goat anti-mouse IgG-R-PE).
Sequence analysis
Peptide helical-wheel calculations were accomplished with the HeliQuest tool (http://heliquest.ipmc.cnrs.fr) [32] . Sequence similarities were calculated with CLUSTALW (http://npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=/NPSA/ npsa_clustalw.html).
Primary cells and cell lines
HL60 cells stably transfected with human FPR1 or FPR2 have been described recently [33, 34] . These cells were grown in RPMI medium (Biochrom, Cambridge, United Kingdom), supplemented with 10% FCS (Sigma-Aldrich, St. Louis, MO, USA), 20 mM HEPES (Biochrom), penicillin (100 units/ml), streptomycin (100 mg/ml; Gibco, Life Technologies, Grand Island, NY, USA), and 13 Glutamax (Gibco, Life Technologies). Transfected cells were grown in the presence of G418 (Biochrom) at a final concentration of 1 mg/ml.
Neutrophil chemotaxis
Human neutrophils were isolated by standard Ficoll/Histopaque gradient centrifugation. Chemotaxis toward synthetic peptides was determined by use of fluorescence-labeled neutrophils that migrated through a 3 mm poresize polycarbonate Transwell filter, as described recently [13] . In brief, 5 3 10 6 neutrophils/ml were labeled with 3.3 mM bis-2-carboxyethyl-5-[and-6]-carboxyfluorescein-AM (Molecular Probes, Leiden, Netherlands) for 20 min at room temperature, washed, and resuspended in HBSS-HSA. The upper compartment of the Transwell system was filled with 100 ml-labeled neutrophils and placed into a well containing 600 ml HBSS-has, with or without chemoattractants (e.g., fMLF or b-type PSMs), and placed into a well. After incubation at 37°C under 5% CO 2 for 80 min, the inserts were removed, and the fluorescence of the wells was read in a fluorescence reader (FLUOstar OPTIMA; BMG Labtech, Ortenberg, Germany).The fluorescence measured was used to monitor migration after subtracting the background migration of HBSS-HSA. Peptides were used at concentrations of 50 nM, 500 nM, 1 mM, 5 mM, and 10 mM for b-type PSMs and 0.1 nM, 0.5 nM, 1 nM, 10 nM, 100 nM, and 1000 nM for fMLF. The measured relative fluorescence was corrected for buffer controls (buffer added only to lower compartment).
Measurement of calcium ion fluxes in human neutrophils and HL60 cells
Calcium fluxes were analyzed by stimulating cells loaded with Fluo-3-AM (Molecular Probes) and monitoring fluorescence with a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA), as described recently [13] . Synthetic chemoattractants were used at concentrations in the linear range of the dose-response curves. To stimulate HL60 cells, all peptides were used at the following concentrations: 10 nM, 100 nM, 250 nM, 500 nM, 1 mM, 2.5 mM, 5 mM, and 10 mM. To stimulate neutrophils, all peptides were used at the following concentrations: 50 nM, 500 nM, 1 mM, 2.5 mM, 5 mM, and 10 mM. Measurements of 2000 events were performed, and calcium flux was expressed as relative fluorescence corrected for buffer controls.
IL-8 production
Human IL-8 was measured by use of an ELISA kit (R&D Systems), according to the manufacturer's instructions. Neutrophils were incubated with indicated concentrations of the different peptides for 5 h at 37°C, 5% CO 2 . Then, cells were centrifuged for 10 min at 250 g and 4°C, and cell supernatants were stored at 220°C before use [21] .
Cell lysis
Lysis of neutrophils by 8 mM full-length or truncated PSMs was determined by measuring the release of cytoplasmic LDH (Cytotoxicity Detection Kit; Roche Diagnostics, Indianapolis, IN, USA), as described recently [21] .
CD11b up-regulation
Activation of human neutrophils was determined by measuring surface expression of CD11b. Neutrophils were incubated with 5 mM PSMs at 37°C with rotation for 60 min as described elsewhere [21] . Cells were stained with a PE-labeled antibody against CD11b (mAb 44; BD Biosciences) or isotype control antibody (BD Biosciences). Then, neutrophils were analyzed on a FACSCalibur flow cytometer (BD Biosciences).
CD spectroscopy
CD spectra were measured by use of a Jasco J-810 instrument at room temperature. Cuvettes with a 0.1 cm path were used; 5 spectra were averaged at a scan speed of 50 nm/min, band width of 1 nm, and data pitch of 0.1 nm. Peptides were measured at a concentration of 50 mg/ml in water with 5% trifluoroethanol.
Statistical methods
Statistical analyses were performed with the Prism 4.0 package (GraphPad Software, La Jolla, CA, USA) and the between-group differences were analyzed for significance with the unpaired Student's t-test.
RESULTS
b-Type PSM length is critical for a stable secondary structure and hydrophobic) properties are most pronounced in the Cterminal halves but extend over the entire length of the peptides (Fig. 1) . SaPSMb1 is more related to SePSMb1 than to SLUSH-B over the entire peptide length (77.3% vs. 63.6% similarity, respectively; Supplemental Table 1 ).
To analyze if shorter fragments of b-type PSMs may have similar biologic activities as the full-length peptide synthetic SLUSH-B, congeners with stepwise truncation from the N and C terminus were generated. In addition, the N-terminal and C-terminal halves of SaPSMb1 and SePSMb1 were synthesized for functional studies (Table 1 ). The full-length and N-terminal peptides were generated as formylated peptides. As we noted that SLUSH-B bears a methionine at the junction between N-and C-terminal halves, in contrast to the other 2 b-type PSMs, the C-terminal SLUSH-B fragment SLUSH-B(C21) was generated in the formylated and nonformylated state to analyze whether formylation may affect the biologic activity of the C-terminal half of b-type PSMs. Likewise, the N-terminal SLUSH-B(N22) peptide was generated as a formylated and nonformylated peptide ( Table 1) .
As a-helical, amphipathic properties are assumed to be important for the capacity of PSMs to lyse neutrophils and activate FPR2 [17, 20] and as the propensity to form stable a-helices may depend on peptide length, the secondary structures of all 3 b-type PSMs and their subfragments were compared by CD spectroscopy (Fig. 2) . Whereas all investigated, full-length b-type PSMs exhibited typical a-helical spectra, the truncated peptides behaved more like unfolded peptides, indicating that their secondary structure is less stable compared with the full-length peptides. A SLUSH-Brev did not exhibit an a-helical structure (Fig. 2B) , indicating that the amino acid sequence is a crucial determinant for b-type PSM to form stable secondary structures.
Peptide length and formylation govern the capacities of b-type PSMs to attract, lyse, and activate human neutrophils SaPSMb1, SePSMb1, and SLUSH-B have been shown to induce chemotactic migration of neutrophils [12, 21] , raising the question of whether this property requires full-length peptides or may also be found in b-type PSM fragments. We found that all formylated N-terminal peptide fragments of the 3 b-type PSMs are chemoattractants for human neutrophils, and the shorter fragments were even stronger attractants than the full-length peptides (Fig. 3A-C) . None of them was as active, though, as the most potent, known formylated peptide, fMLF (Fig. 3D) . The nonformylated N-terminal SLUSH-B(N22) peptide did not induce migration of neutrophils (Fig. 3A) . Notably, the formylated C-terminal fragment SLUSH-B(C21) also recruited neutrophils, but this activity was absent from the corresponding nonformylated peptide (Fig. 3A) . The SLUSH-Brev peptide with a reversed amino acid sequence had no activity, probably as it neither bore a formylated methionine at its N terminus nor exhibited a stable secondary structure (Fig. 3D) . Very similar results were obtained when neutrophil calcium fluxes were measured (Supplemental Fig. 1) . Thus, b-type PSMs do not need their full length to attract neutrophils, but all shortened peptides require N-terminal formylation to exert this activity.
To investigate if the neutrophil-attracting properties of b-type PSM fragments correspond to their cytotoxic activity, the capacities of the various peptides to disrupt human neutrophils were compared. We found that full-length b-type PSMs have rather weak but notable cytolytic activities at micromolar concentrations. All 3 full-length b-type PSMs (8 mM) led to lysis of ;30% of neutrophils (Fig. 4A-C) . In contrast, none of the N-and C-terminally shortened b-type PSM fragments had obvious cytolytic activities, indicating that it is possible to separate the cytolytic and chemoattractant ways of PSMs to affect leukocytes (Fig. 4A-C) .
When the capacities of the 3 b-type PSMs to stimulate IL-8 release or CD11b up-regulation in human neutrophils were analyzed, SaPSMb1 was found to induce stronger CD11b upregulation (Fig. 5B) and IL-8 secretion (Supplemental Fig. 2B ) than SLUSH-B and SePSMb1 (Fig. 5A and C and Supplemental Fig. 2A and C) . None of the nonformylated N-terminal or C-terminal fragments had such an activity. In contrast, all formylated N-terminal fragments and the formylated SLUSH-B (C21) induced CD11b up-regulation ( 
FPR1 and FPR2 discriminate between b-type PSM variants based on peptide length and formylation
The various ways of b-type PSM fragments to modulate neutrophil functions raised the question of whether they can activate FPR2 or FPR1 in a similar way as the full-length peptides. HL60 cells, stably transfected with FPR1 or FPR2, and untransfected cells (Supplemental Fig. 4 ) [34] were stimulated with the various peptides, and calcium influx was measured as an established read-out for activation of FPRs [13] .
The shortest N-terminal SLUSH-B fragment, SLUSH-B(N10), had no FPR2-stimulating but pronounced FPR1-stimulating activity (Fig. 6A) . N-Terminal SLUSH-B fragments with lengths similar to those of a-type PSMs (18 aa or longer), however, had notable capacities to activate FPR2, which increased with length and reached the maximum in the 26 aa-long variant and in fulllength SLUSH-B (Fig. 6A) . Conversely, FPR1 activation declined with peptide length and was close to zero in full-length SLUSH-B (Fig. 6A) . The N-terminal half of the S. epidermidis peptide SePSMb1(N22) (Fig. 6C ) also activated FPR2 in a similar way as SLUSH-B(N22). However, SaPSMb1(N22) (Fig. 6B ) differed from the 2 corresponding peptides, as it did not stimulate FPR2 but had substantial FPR1-stimulating activity. The absence of a formyl group in SLUSH-B(N22) abolished all activity to any of the 2 receptors (Fig. 6A) . Thus, peptide length is a crucial parameter for the capacity of b-type PSM fragments to activate FPR2.
Notably, the formylated but not the nonformylated C-terminal half of SLUSH-B also had potent activity toward FPR2 and only weak activity to FPR1 (Fig. 6A) . Together, these data indicate that the capacity of b-type PSMs to activate FPR2 does not require the full length of 42 aa but that shortened peptides can do so as long as they reach a certain length and bear an N-terminal formyl group.
DISCUSSION
FPR2 recognizes a growing list of virtually unrelated peptides, raising the question as to which molecular pattern may be recognized by this receptor [4, 35] . It has been shown previously that FPR1 recognizes a defined microbial molecular pattern, N-formylated methionine, followed by hydrophobic amino acids [36, 37] , but it is still not clear which structural features define an FPR2 ligand [4, 6, 9, 10] . By truncating b-PSMs stepwise, we found that differences in PSM length and folding state have crucial impacts on the propensities of the peptides to stimulate FPR1 or FPR2. Reduced activation of FPR2 correlated in all 3 N-terminal peptides with increased FPR1 activation and vice versa, indicating that the 3 receptors have opposed ligand specificities. Short, formylated peptides are only very weak agonists for FPR2, although their activity increases with peptide length [20, 36, 38] . A recent study demonstrated that the shortening of a-type PSMs from the C terminus reduced their capacity to activate FPR2, which further corroborates the notion that peptide length is critical for FPR2 stimulation [20] . Nonformylated peptides with a-helical, amphipathic properties, such as human LL-37 [11] ; the Helicobacter pylori peptide Hp [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] 39] ; or nonformylated, fulllength a-of b-type PSMs [13] have intermediary capacities to activate FPR2, suggesting that such a secondary structure is a preferred motif for FPR2 [4] . The strongest, FPR2-specific activities have been reported for PSMs that combine N-terminal formylation and a-helical and amphipathic secondary structures [13] . At the same time, formylated, full-length PSMs are only very weak FPR1 agonists, suggesting that a stable secondary structure compromises their interaction with FPR1 [13] .
The truncated, formylated b-type PSMs used in this study activated FPR2 only when they were 18 aa or longer. a-Type PSMs are in a similar size range and have documented a-helical structures, which is agreement with the assumption that such a secondary structure represents a crucial molecular pattern for FPR2 recognition. In contrast to the full-length b-type PSMs, the truncated peptides did not form stable a-helical structures in CD experiments. The stability of secondary structures is known to increase with peptide length, and many peptides adopt defined structures only when bound to a receptor protein [40] . With the consideration that CD experiments need to be carried out at rather artificial buffer conditions, it is tempting to assume that even the truncated b-type PSMs above 18 aa can form amphipathic a-helices in complex with FPR2 as a prerequisite for FPR2 activation. The fact that the capacity of all truncated b-type PSMs to activate FPR2 depended on N-terminal formylation may be a result of the instability of secondary structures, which may require an initial interaction of the peptides with FPR2 via the formylated N terminus. On the other hand, the increased structural flexibility of the truncated b-type PSMs compared with native PSMs was reflected by the notable capacity of such peptides to activate FPR1. Similar observations were recently made with shortened a-type PSMs [20] . Thus, a stable a-helical and amphipathic structure appears to favor FPR2 but not FPR1 activation, whereas a shorter, undefined, flexible secondary structure may favor FPR1 but not FPR2 activation. It remains unclear why the N-terminal half of the S. aureus b-type PSM did not activate FPR2 at all. Its propensity to adopt a stable secondary structure may be even weaker than those of the corresponding parts of the S. lugdunensis and S. epidermidis peptides, which are more related to each other in terms of sequence than to SaPSMb1(N22) (Supplemental Table 1 ).
It is interesting to note that increased FPR1 compared with FPR2 activation by b-type PSMs and their subfragments was accompanied by stronger neutrophil chemotaxis and calcium influx, suggesting that FPR1 may be more abundant or may have a stronger capacity to elicit such responses in primary leukocytes than FPR2. The cytotoxic properties of b-type PSMs did not correspond to their receptor-activating capacities, as only the fulllength b-type PSMs had such an activity. Likewise, the shortening of a-type PSMs leads to loss of cytotoxicity, whereas some FPR2-stimulating activity can still be observed [20] . It seems that very stable a-helical and amphipathic properties are required for the peptides to disrupt leukocyte membranes. FPR2 has been proposed to sense specifically the abundance of peptide toxins as a measure of pathogen virulence, whereas FPR1 detects bacterial formylated peptides in general [12] . The fact that reduced folding of PSMs simultaneously abrogates cytotoxicity and changes the capacity to stimulate FPR2 fits well with this concept and underscores the potential role of FPR2 as a receptor for true pathogen-associated molecular patterns. The patterns of IL-8 activation by the various peptides were somewhat intermediary between those observed for CD11b up-regulation and cytotoxicity, suggesting that both-receptor-dependent and membranedamaging-activities may contribute to the release of IL-8 from intracellular neutrophil compartments [41] .
It remains unclear why staphylococci produce b-type PSMs in addition to a-type PSMs. Notably, the N-terminal and C-terminal half of SLUSH-B could activate FPR2 as long as it was formylated. suggesting that b-type PSMs may have evolved from a-type PSMs by extension or duplication. Sequence alignments revealed that the b-type PSMs possess much higher similarity among PSMs of different species than a-type PSMs [12] , suggesting that their primary sequence may have a more important functional role. b-Type PSMs are more abundantly secreted than a-type PSMs, except d-toxin [21, 42] , although their cytotoxic and proinflammatory activities are lower than those of a-type PSMs [21] , suggesting that another function may be more important. In line with this notion, b-type PSMs play a more important role in biofilm detachment and structuring than a-type PSMs, which may be crucial in vivo [43] . We have found that secretion of high amounts of FPR2 ligands is typical for staphylococci, whereas many other bacteria, including Escherichia coli and Yersinia enterocolitica, secrete only FPR1 ligands [18] . How exactly FPRs recognize ligand peptides and if activation of the various FPRs has different consequences in leukocytes should be studied in the future. Such studies will help to develop new strategies to combat severe staphylococcal infections, e.g., by generating antagonists of FPR2 that would inhibit overwhelming inflammatory responses in acute infections induced by highly pathogenic S. aureus. 
